Loading...
This record has been deleted. Since it is linked to a published record, it is available here for reference purposes only.
Click here to view the deleted recordThis document has been updated. This is not the latest published version. Click here to view the latest version of the record.
Living Modified Organism
(LMO)
The image below identifies the LMO through its unique identifier, trade name and a link to this page of the BCH. Click on it to download a larger image on your computer. For help on how to use it go to the LMO quick-links page.
INNOVAX-ND-IBD
EN
HVT/NDV-F/IBDV-VP2
No
-
Person:Dr Marielle Van HultenDirector of Biology Discovery, EU Geohead PoultryIntervet International BV Wim de Korverstraat 35 Boxmeer the NetherlandsBoxmeer,
, Netherlands (Kingdom of the)Phone: +31485587172,Fax:Email: marielle.vanhulten@merck.com,Website:Related OrganizationMSD Animal Health ()Private sector (business and industry)Intervet International BV Wim de Korverstraat 35 Boxmeer the NetherlandsBoxmeer,
, Netherlands (Kingdom of the)Phone: +31485587172,Fax:Email: marielle.vanhulten@merck.com,Website:
Innovax-ND-IBD is a live recombinant vaccine based on Turkey herpesvirus (Meleagrid alphaherpesvirus 1) containing expressing fusion protein from Newcastle disease virus (Orthoavulavirus javaense) and viral protein 2 from Infectious bursal disease virus (Avibirnavirus gumboroense). Thus, the recombinant viral vaccine Innovax-ND-IBD gives protection against Marek’s disease, Newcastle disease and infectious bursal disease.
The term “Recipient organism” refers to an organism (either already modified or non-modified) that was subjected to genetic modification, whereas “Parental organisms” refers to those that were involved in cross breeding or cell fusion.
-
BCH-ORGA-SCBD-105225-3 Organism Meleagrid alphaherpesvirus 1 (Turkey herpesvirus, Meleagrid herpesvirus 1)Viruses
Meleagrid herpesvirus 1 strain FC-126
EN
HVP360
EN
- Other (Recombination)
|
0.000 kb
|
|
0.000 kb
|
|
0.000 kb
|
|
0.000 kb
|
|
0.000 kb
|
|
0.000 kb
|
Some of these genetic elements may be present as fragments or truncated forms. Please see notes below, where applicable.
-
BCH-GENE-SCBD-105223-1 Viral Protein 2 gene | Infectious bursal disease virus (Gumboro virus)Protein coding sequence | Production of medical or pharmaceutical compounds (human or animal) (Vaccines)
-
BCH-GENE-SCBD-277346-1 Immediate-Early 1 promoter | Muromegalovirus muridbeta1 (Murine cytomegalovirus, Mouse cytomegalovirus 1, MCMV1)Promoter
-
BCH-GENE-SCBD-105090-4 Fusion protein gene | Avian orthoavulavirus 1 (Newcastle disease virus, NDV)Protein coding sequence | Production of medical or pharmaceutical compounds (human or animal) (Vaccines)
-
BCH-GENE-SCBD-277347-1 Immediate-early protein terminator | Cytomegalovirus humanbeta5 (Human cytomegalovirus, HCMV, HHV-5)Terminator
-
BCH-GENE-SCBD-114748-3 SV40 poly-adenylation signal | Macaca mulatta polyomavirus 1 (SV40, Simian vacuolating virus 40, simian virus 40, Rhesus macaque polyomavirus)Terminator
-
BCH-GENE-SCBD-115609-1 Major immediate early promoter containing intron A | Human betaherpesvirus 5 (Human cytomegalovirus, HCMV, HHV-5)Promoter
The modified turkey herpesvirus contains two gene cassettes for the expression of the antigens Orthoavulavirus javaense (Newcastle disease virus) fusion protein and Avibirnavirus gumboroense (Infectious bursal disease virus) viral protein 2.
The expression of fusion protein is under control of a Cytomegalovirus humanbeta5 immediate-early promoter and terminator. The expression of the fusion protein was enhanced by the presence of an intron associated with the promoter. The protein coding sequence was sourced from NDV Genotype II Clone 30.
The expression of viral protein 2 is under control of a Muromegalovirus muridbeta1 immediate-early promoter and a Macaca mulatta polyomavirus 1 (SV40) polyadenylation signal. The protein coding sequence was sourced from IBDV strain Faragher 52/70.
The expression of fusion protein is under control of a Cytomegalovirus humanbeta5 immediate-early promoter and terminator. The expression of the fusion protein was enhanced by the presence of an intron associated with the promoter. The protein coding sequence was sourced from NDV Genotype II Clone 30.
The expression of viral protein 2 is under control of a Muromegalovirus muridbeta1 immediate-early promoter and a Macaca mulatta polyomavirus 1 (SV40) polyadenylation signal. The protein coding sequence was sourced from IBDV strain Faragher 52/70.
EN
- Vaccine
EN
EN
